Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Orvacabtagene autoleucel - Juno Therapeutics

Drug Profile

Orvacabtagene autoleucel - Juno Therapeutics

Alternative Names: Anti BCMA CAR T cell therapy - Juno Therapeutics; Anti-BCMA CAR - Juno Therapeutics; Anti-BMCA Chimeric antigen receptor cell therapy-Juno Therapeutics; BCMA-CAR-T-Juno Therapeutics; BCMA-specific CAR expressing T-Lymphocytes-Juno Therapeutics; BCMA-specific CAR-T-Juno Therapeutics; BCMA-Targeted CAR-T Cells-Juno Therapeutics; EGFRt/BCMA 41BBz CAR-T cell; ET 140; ET140 CAR; FCARH143; JCARH-125; MCARH171; orva-cel

Latest Information Update: 20 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Juno Therapeutics
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple myeloma

Most Recent Events

  • 07 Dec 2019 Efficacy data from a phase I trial Multiple myeloma presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-2019)
  • 03 Dec 2018 Interim adverse events and efficacy data from phase I/II Evolve trial in Multiple myeloma presented at the 60th American Society of Hematology Annual Meeting (ASH-Hem-2018)
  • 01 Dec 2018 Final adverse events and efficacy data from a phase I trial in Multiple myeloma presented at the 60th American Society of Hematology Annual Meeting (ASH-Hem-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top